Hinge Health CEO Daniel Perez sells over $410k in company stock

Daniel Antonio Perez, CEO and Co-Founder of Hinge Health, Inc. (NASDAQ:HNGE), a Director, and a 10% owner, sold 4,100 shares of the company’s Class A Common Stock on October 6, 2026. The total value of the shares sold amounted to $410,810.

The shares were sold at prices ranging from $100.05 to $100.26, with a weighted average sale price of $100.1978 per share. This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Perez and his spouse on June 11, 2026. The sale occurred with the stock trading near its 52-week high of $100.36, following a remarkable 156% surge over the past six months.

Prior to the sale, Mr. Perez acquired 4,100 shares of Class A Common Stock at a price of $0.0. This acquisition appears to be related to the conversion of Class B Common Stock, as 4,100 shares of Class B Common Stock, convertible into Class A Common Stock, were also reported as acquired on the same date at an exercise price of $0.0. Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the election of the holder or automatically upon certain events.

Following these transactions, Mr. Perez directly holds no Class A Common Stock. He continues to directly hold 9,774,572 shares of Class B Common Stock. Additionally, his spouse indirectly holds 35,470 shares of Class A Common Stock and 208,445 shares of Class B Common Stock. The reported holdings exclude 3,777,002 performance-based restricted stock units held by Mr. Perez.The insider sale comes as Hinge Health, valued at $7.9 billion, appears overvalued according to InvestingPro analysis. For deeper insights into HNGE’s valuation and 14 additional InvestingPro Tips, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, Hinge Health has been the focus of several analyst updates following its recent developments. Truist Securities raised its price target for Hinge Health to $112, reflecting a revised financial model based on the company’s second-quarter earnings results and a pending acquisition of Cylinder Health. Truist now projects Hinge Health’s revenue to reach $860 million for fiscal 2026 and $1,095 million for fiscal 2027. Similarly, Stifel increased its price target to $115, maintaining a Buy rating, citing a strong growth outlook with projections of over 33% growth by 2027, surpassing the consensus estimate of 27%.

BofA Securities also initiated coverage on Hinge Health with a Buy rating and a price target of $110. Additionally, Truist Securities reiterated its Buy rating and $112 price target during its West Coast Bus Tour after discussions with the company’s leadership. Stifel had previously raised its price target to $96, acknowledging the company’s outperformance following a pre-release announcement. These updates indicate a positive sentiment among analysts regarding Hinge Health’s future prospects.